IN2014DN10404A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10404A
IN2014DN10404A IN10404DEN2014A IN2014DN10404A IN 2014DN10404 A IN2014DN10404 A IN 2014DN10404A IN 10404DEN2014 A IN10404DEN2014 A IN 10404DEN2014A IN 2014DN10404 A IN2014DN10404 A IN 2014DN10404A
Authority
IN
India
Prior art keywords
pde7
addictions
phosphodiesterase
directed
disclosure
Prior art date
Application number
Other languages
English (en)
Inventor
Gregory A Demopulos
George A Gaitanaris
Roberto Ciccocioppo
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/835,607 external-priority patent/US9220715B2/en
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of IN2014DN10404A publication Critical patent/IN2014DN10404A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN10404DEN2014 2012-05-07 2013-05-07 IN2014DN10404A (enrdf_load_stackoverflow)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643611P 2012-05-07 2012-05-07
US13/835,607 US9220715B2 (en) 2010-11-08 2013-03-15 Treatment of addiction and impulse-control disorders using PDE7 inhibitors
PCT/US2013/039866 WO2013176877A2 (en) 2012-05-07 2013-05-07 Treatment of addiction and impulse-control disorders using pde7 inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN10404A true IN2014DN10404A (enrdf_load_stackoverflow) 2015-08-14

Family

ID=49624481

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10404DEN2014 IN2014DN10404A (enrdf_load_stackoverflow) 2012-05-07 2013-05-07

Country Status (10)

Country Link
EP (1) EP2846805B1 (enrdf_load_stackoverflow)
JP (1) JP2015521177A (enrdf_load_stackoverflow)
CN (3) CN114984229A (enrdf_load_stackoverflow)
AU (1) AU2013266793B2 (enrdf_load_stackoverflow)
CA (1) CA2871151C (enrdf_load_stackoverflow)
IN (1) IN2014DN10404A (enrdf_load_stackoverflow)
PL (1) PL2846805T3 (enrdf_load_stackoverflow)
RS (1) RS58381B1 (enrdf_load_stackoverflow)
SI (1) SI2846805T1 (enrdf_load_stackoverflow)
WO (1) WO2013176877A2 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
MX389018B (es) 2010-11-08 2025-03-20 Omeros Corp Tratamiento de trastornos de adiccion y control de impulsos usando inhibidores de pde7.
TW201811782A (zh) * 2016-08-26 2018-04-01 日商田邊三菱製藥股份有限公司 二環式含氮雜環化合物
WO2023243659A1 (ja) * 2022-06-15 2023-12-21 真一 松本 線条体ストリオソームのドパミンｄ１シグナルを標的とした強迫性障害の薬物療法
JP2025527566A (ja) * 2022-08-18 2025-08-22 ミトディキュア・ゲー・エム・ベー・ハー 慢性疲労、疲労困憊及び／又は労作不耐症に関連する疾患の処置及び予防のための、ホスホジエステラーゼ－７阻害活性を有する治療剤の使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932250B2 (en) * 2004-07-01 2011-04-26 Daiichi Sankyo Company, Limited Thienopyrazole derivative having PDE7 inhibitory activity
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
EP1928438B1 (en) * 2005-09-26 2013-03-20 Avigen, Inc. Use of ibudilast for treating drug addictions
AU2008230710B2 (en) * 2007-03-27 2014-04-10 Omeros Corporation The use of PDE7 inhibitors for the treatment of movement disorders
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US8426439B2 (en) * 2007-04-11 2013-04-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
MX389018B (es) * 2010-11-08 2025-03-20 Omeros Corp Tratamiento de trastornos de adiccion y control de impulsos usando inhibidores de pde7.

Also Published As

Publication number Publication date
EP2846805A2 (en) 2015-03-18
CA2871151C (en) 2019-03-26
CA2871151A1 (en) 2013-11-28
AU2013266793A1 (en) 2014-11-27
CN104768556A (zh) 2015-07-08
WO2013176877A3 (en) 2015-06-18
SI2846805T1 (sl) 2019-04-30
JP2015521177A (ja) 2015-07-27
EP2846805A4 (en) 2016-08-10
CN112168972A (zh) 2021-01-05
EP2846805B1 (en) 2018-11-21
WO2013176877A2 (en) 2013-11-28
CN114984229A (zh) 2022-09-02
AU2013266793B2 (en) 2016-08-04
PL2846805T3 (pl) 2019-05-31
RS58381B1 (sr) 2019-04-30

Similar Documents

Publication Publication Date Title
MX389018B (es) Tratamiento de trastornos de adiccion y control de impulsos usando inhibidores de pde7.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
PL2825161T3 (pl) Inhibitory ludzkiej ezh2 i sposoby ich zastosowania
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
IN2014CN04014A (enrdf_load_stackoverflow)
PH12015502302A1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
MX2014014839A (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
PH12014500925A1 (en) Therapeutic combinations and methods of treating melanoma
IN2014DN10404A (enrdf_load_stackoverflow)
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
MY200803A (en) Mpo inhibitors for use in medicine
ZA201600312B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina
SI2790687T1 (sl) TRPC4 modulatorji za uporabo pri zdravljenju ali preprečevanju bolečine
HUE043518T2 (hu) Függõség és impulzuskontroll zavarok kezelése PDE-7-inhibitorok alkalmazásával
EP2934699A4 (en) PLOD2 GENE STIMULATORS AND USE OF SAID STIMULATORS FOR TREATING SKIN
MX2013006527A (es) Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos.